Northern Trust
ACTU

Northern Trust’s Actuate Therapeutics ACTU Stock Holding History

Northern Trust’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.5K Sell
21,220
-76,631
-78% -$178K ﹤0.01% 4322
2026
Q1 		$268K Sell
97,851
-3,572
-4% -$14.8K ﹤0.01% 3846
2025
Q4 		$621K Buy
101,423
+15,969
+19% +$110K ﹤0.01% 3581
2025
Q3 		$572K Sell
85,454
-240
-0.3% -$1.74K ﹤0.01% 3605
2025
Q2 		$524K Buy
85,694
+31,842
+59% +$278K ﹤0.01% 3630
2025
Q1 		$365K Buy
+53,852
New +$432K ﹤0.01% 3709

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Northern Trust's ACTU Position: Q2 2026 in Review

Northern Trust reduced its Actuate Therapeutics (ACTU) stake by 78% in Q2 2026, selling an estimated $178K and leaving 21,220 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

Northern Trust first reported a position in ACTU in Q1 2025 and has held it in 6 quarters since. The position peaked at $621K in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Northern Trust held 21,220 shares of Actuate Therapeutics worth $32.5K as of Q2 2026.
  • Northern Trust sold 76,631 Actuate Therapeutics shares in Q2 2026, an estimated $178K.
  • Actuate Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4322 holding.
  • Northern Trust first reported a position in Actuate Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Northern Trust's Actuate Therapeutics position peaked at $621K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.